Back

Mavacamten to treat patients with obstructive HCM in Portugal: an interim analysis of the MAVA-PT cohort

10 May 2026 (14:30 - 14:39)
Organised by: Logo
Congress Presentation Part of: Novel and targeted therapies: precision pharmacology in heart failure Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Debora Da Silva Correia

Hospital Santa Cruz, Lisbon (Portugal)

4 More presentations in this session

Presentation thumbnail
The influence of QRS duration and resynchronization status on the efficacy and safety of omecamtiv mecarbil in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Assistant Professor M. Ruppert (Boston, US)
Abstract Slides Video
Presentation thumbnail
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
Doctor G. Mendieta Badimon (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Effect of aficamten compared with metoprolol in women versus men: analysis of MAPLE-HCM
Doctor X. Wang (Boston, US)
Abstract Slides Video
Presentation thumbnail
Ferric carboxymaltose modulates metabolic and inflammatory pathways alongside erythropoiesis in heart failure: mechanistic insights from the AFFIRM-AHF
Doctor N. Grote Beverborg (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Novel and targeted therapies: precision pharmacology in heart failure
Video

The Event

Event poster

Heart Failure 2026

10 May 2026 14:30 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources